glp-1 small molecule agonist A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency Peptidyl and Non-Peptidyl Oral Glucagon-Like

GLP-1R agonists effect(s) on vascular smooth muscle cells are equally important to those on endothelial cells with several favorable responses being reported, including enhanced differentiation, attenuated response to reactive oxygen species, reduced vascular remodeling through improved mitochondrial activity and dynamics, and the prevention of aberrant migration [65]

*Correspondence: Elisabet Jerlhag, [email protected] This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

doi: 10.1186/s12933-018-0800-2 [DOI] [PMC free article] [PubMed] [Google Scholar] 198

North America Maintains Leadership While Asia Pacific Emerges as the Fastest-Growing Market North America held about 45% share of GLP-1 Receptor Agonists Market in 2025 on account of favorable reimbursement scenario in the US, high-cost drugs, high adoption rate of doctors, and heavy commercialization efforts of Novo Nordisk and Eli Lilly

Sclerostin regulation, microarchitecture, and advanced glycation end-products in the bone of elderly women with type 2 diabetes